Please use this identifier to cite or link to this item:
|Title: ||Immunotherapy for lung cancers|
|Authors: ||Ming-Yi Ho;Shye-Jye Tang;Kuang-Hui Sun;Winnie Yang|
|Issue Date: ||2016-09-01T06:24:34Z
|Publisher: ||Journal of Biomedicine and Biotechnology|
|Abstract: ||Abstract: Lung cancer is the leading cause of cancer-related deaths worldwide. Although treatment methods in surgery, irradiation, and
chemotherapy have improved, prognosis remains unsatisfactory and developing new therapeutic strategies is still an urgent
demand. Immunotherapy is a novel therapeutic approach wherein activated immune cells can specifically kill tumor cells by
recognition of tumor-associated antigens without damage to normal cells. Several lung cancer vaccines have demonstrated
prolonged survival time in phase II and phase III trials, and several clinical trials are under investigation. However, many clinical
trials involving cancer vaccination with defined tumor antigens work in only a small number of patients. Cancer immunotherapy
is not completely effective in eradicating tumor cells because tumor cells escape from host immune scrutiny. Understanding of
the mechanism of immune evasion regulated by tumor cells is required for the development of more effective immunotherapeutic
approaches against lung cancer. This paper discusses the identification of tumor antigens in lung cancer, tumor immune escape
mechanisms, and clinical vaccine trials in lung cancer.
|Appears in Collections:||[生命科學系] 期刊論文|
Files in This Item:
There are no files associated with this item.
All items in NTOUR are protected by copyright, with all rights reserved.